Stocks making the biggest moves in the premarket: Gilead Sciences, Starbucks, BP, Coty & more

Stocks making the biggest moves in the premarket: Gilead Sciences, Starbucks, BP, Coty & more

Take a look at some of the biggest movers in the premarket:

Gilead Sciences (GILD) - Gilead set pricing for its remdesivir anti-viral Covid-19 treatment, with developed-world governments paying $390 per dose and privately insured patients being charged $520 per dose.

Intercept Pharmaceuticals (ICPT) - The Food and Drug Administration did not approve the company's treatment for obesity-linked liver disease. Intercept said it would meet with the FDA to discuss possible paths to approval.

Starbucks (SBUX), Coca-Cola (KO) - Starbucks and Coca-Cola both announced pauses in social media ads, in the latest actions against hate speech on platforms like Facebook (FB) and Twitter (TWTR). Similar actions were announced by spirits producer Diageo (DEO) and chocolate maker Hershey (HSY).

BP (BP) - BP announced the sale of its petrochemicals business to privately held U.K. chemicals company Ineos for $5 billion. BP said the move means it has met its $15 billion divestments target a year ahead of schedule.

Novartis (NVS) - Novartis pulled its application for European approval of its dry-eye drug Xiidra after regulators said its effectiveness had not been demonstrated. The drug is already approved in the U.S.

Amazon.com (AMZN) - Amazon and Japan's SoftBank have both approached Russian conglomerate Sistema about a possible buyout of